India, Aug. 14 -- THL Partners, Thursday announced an agreement to Headlands Research, a multinational network of clinical trial sites, from funds managed by KKR & Co. Inc. (KKR).
The deal is expected to boost Headlands' continued expansion, enhance its technology and centralized infrastructure, and further strengthen its ability to deliver high-quality, diverse clinical trial data for pharmaceutical and biotech sponsors.
THL will finance the deal, expected to close this year, with its flagship Fund IX.
Currently, KKR is trading at $146.40, down 0.81 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....